Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 6/20 | 0.78 |
| ▸ | F7 | P08709 | 1/20 | 0.57 |
| ▸ | F3 | P13726 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GUSB | P08236 | 1/20 | 0.54 |
| ▸ | PYGL | P06737 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308355 | 0.88 | NHERF1 (0.81) | NHERF1F7F3MEN1KMT2A | |
| SCHEMBL14503742 | 0.86 | NHERF1 (0.62) | NHERF1MEN1KMT2ARXFP1PYGL | |
| SCHEMBL5410224 | 0.86 | NHERF1 (0.67) | NHERF1F7F3MEN1KMT2A | |
| SCHEMBL1306446 | 0.85 | NHERF1 (0.74) | NHERF1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL14503746 | 0.85 | NHERF1 (0.67) | NHERF1F7F3MEN1KMT2A | |
| SCHEMBL5410974 | 0.84 | NHERF1 (0.65) | NHERF1F7F3MEN1KMT2A | |
| SCHEMBL14503747 | 0.82 | NHERF1 (0.63) | NHERF1MEN1KMT2ARXFP1NPC1 | |
| SCHEMBL1310023 | 0.82 | NHERF1 (0.73) | NHERF1F7F3MEN1KMT2A | |
| SCHEMBL31058769 | 0.81 | NHERF1 (0.78) | NHERF1F7F3MEN1KMT2A | |
| SCHEMBL5405858 | 0.81 | NHERF1 (0.67) | NHERF1F7F3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223786-B2 | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223786-B2 | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223786-B2 | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| WO-2006055435-A1 | 2-AMINONAPHTHALENE DERIVATIVES AND RELATED GLYCOGEN PHOSPHORYLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111415-A1 | 2-Aminonaphthalene derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111415-A1 | 2-Aminonaphthalene derivatives and related glycogen phosphorylase inhibitors | PYGM, GYS1, PYGL | NHERF1 3138/4885F7 4718/4885F3 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.